Pharmaceutical - Cardio-vascular

Filter

Current filters:

Cardio-vascular

Popular Filters

1 to 25 of 423 results

Sanofi showcases next wave of medicines and vaccines

20-11-2014

French pharma major Sanofi is today outlining its intention to launch high-potential new medicines and…

Cardio-vascularDiabetesHealth Medical PharmaImmunologicalsNeurologicalPharmaceuticalPharmaceutical industryRare diseasesResearchSanofiUnited StatesVaccines

Positive early results for Boehringer Ingelheim’s investigational antidote idarucizumab

19-11-2014

The US subsidiary of German family-owned pharma major Boehringer Ingelheim has presented Phase I study…

Boehringer IngelheimCardio-vascularHematologyidarucizumabPharmaceuticalPradaxaResearch

Novartis’ LCZ696 reduces the risk of dying and hospitalizations

Novartis’ LCZ696 reduces the risk of dying and hospitalizations

18-11-2014

New data on Swiss drug major Novartis’ investigational medicine LCZ696, for patients with heart failure…

Cardio-vascularLCZ696NovartisPharmaceuticalResearchSwitzerland

AstraZeneca reinforces target of $45 billion revenues by 2023

AstraZeneca reinforces target of $45 billion revenues by 2023

18-11-2014

Anglo-Swedish pharma major AstraZeneca today provided an update for institutional investors and financial…

AstraZenecaCardio-vascularFinancialInflammatory diseasesMetabolicsOncologyPharmaceuticalRespiratory and PulmonaryUK

Merck & Co’s LDL-lowering drug Vytorin meets study endpoints

Merck & Co’s LDL-lowering drug Vytorin meets study endpoints

18-11-2014

Pharma giant Merck & Co has announced that the study investigating LDL-cholesterol-lowering drug Vytorin…

Cardio-vascularMerck & CoPharmaceuticalResearchUSAVytorinZetia

Extended benefit of dual antiplatelet therapy after one year is proven in study

Extended benefit of dual antiplatelet therapy after one year is proven in study

18-11-2014

New research published in the New England Journal of Medicine shows that while dual antiplatelet therapy…

Cardio-vascularClopidogrelPharmaceuticalprasugrelResearchUSA

Study shows mutations in NPC1L1 protein cut coronary heart disease

Study shows mutations in NPC1L1 protein cut coronary heart disease

14-11-2014

A new study part-funded by US pharma giant Merck & Co (NYSE: MRK) has found that mutations in a gene…

Cardio-vascularCoronary heart diseaseMerck & CoPharmaceuticalResearchUnited StatesUSAZetia

Biologics will complement statins in cholesterol treatment space, says GlobalData

Biologics will complement statins in cholesterol treatment space, says GlobalData

11-11-2014

Biologics will play an influential role in shaping the future of cardiovascular drug treatment, in particular…

alirocumabAmgenCardio-vascularevolocumabMarkets & MarketingPharmaceuticalRegeneronSanofiUSA

ScinoPharm and Nanjing King-friend team up to market new drugs in China

ScinoPharm and Nanjing King-friend team up to market new drugs in China

10-11-2014

ScinoPharm Taiwan and China’s Nanjing King-friend Biochemical Pharmaceutical (NKF) announced today…

Cardio-vascularChinaMarkets & MarketingNanjing King-friend BiochemicalPharmaceuticalRegadenoson InjectionResearchScinoPharma Taiwan

EMA PRAC’s recommendations to reduce risk of heart problems with ivabradine

09-11-2014

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has completed a…

AmgenCardio-vascularEuropeivabradinePharmaceuticalProcoralanRegulationServier

Pharming and Salix's Ruconest launches in the USA for hereditary angioedema

Pharming and Salix's Ruconest launches in the USA for hereditary angioedema

03-11-2014

Pharming Group and Salix Pharmaceuticals have launched Ruconest (C1 esterase inhibitor) in the USA for…

Cardio-vascularMarkets & MarketingPharmaceuticalPharming Group NVRuconestSalixUSA

US FDA advisory panel backs Daiichi Sankyo’s Savaysa for stroke risk and SEE

03-11-2014

A US Food and Drug advisory panel has voted in favor of the use of Japanese pharma major Daiichi Sankyo’s…

Cardio-vascularDaiichi SankyoedoxabanPharmaceuticalRegulationSavaysaUSA

NICE recommends Pradaxa for DVT and PE

NICE recommends Pradaxa for DVT and PE

31-10-2014

In draft guidance published today, the UK health costs watchdog the National Institute for Health and…

Boehringer IngelheimCardio-vascularPharmaceuticalPradaxaPricingRegulationUK

UK’s NICE backs another use for Bayer’s Xarelto

UK’s NICE backs another use for Bayer’s Xarelto

23-10-2014

In draft guidance published today for consultation, the UK’s health costs watchdog the National Institute…

BayerCardio-vascularPharmaceuticalPricingRegulationUKXarelto

Viagra found to have potential as heart disease treatment

20-10-2014

Blockbuster erectile dysfunction drug Viagra (sildenafil) could be used as a safe treatment for heart…

Cardio-vascularPfizerPharmaceuticalResearchsildenafilViagra

Boehringer Ingelheim gets two drugs approved by Scotland’s health watchdog

14-10-2014

The UK subsidiary of German family-owned pharma major Boehringer Ingelheim announced today that, following…

Boehringer IngelheimCardio-vascularDiabetesJardiancePharmaceuticalPradaxaPricingUK

Perosphere and Daiichi Sankyo collaborate on Ph III study of PER977 with edoxaban

Perosphere and Daiichi Sankyo collaborate on Ph III study of PER977 with edoxaban

07-10-2014

USA-based Perosphere has entered into a third clinical trial collaboration agreement with Japanese pharma…

Cardio-vascularDaiichi SankyoedoxabanHematologyJapanPER977PerospherePharmaceuticalPortola PharmaceuticalsResearch

Brilinta preferred over clopidogrel in latest AHA/ACC guideline

Brilinta preferred over clopidogrel in latest AHA/ACC guideline

06-10-2014

Anglo-Swedish pharma major AstraZeneca today confirmed that the American Heart Association (AHA) and…

AstraZenecaBrilintaCardio-vascularClopidogrelDaiichi SankyoEli LillyPharmaceuticalprasugrelRegulationSanofiticagrelorUSA

Added indication for Daiichi Sankyo’s Lixiana in Japan

Added indication for Daiichi Sankyo’s Lixiana in Japan

29-09-2014

The Japanese Ministry of Health, Labor and Welfare has granted approval for domestic pharma major Daiichi…

Cardio-vascularDaiichi SankyoJapanLixianaPharmaceuticalRegulation

Takeda and BioMotiv in strategic partnership, including investment

Takeda and BioMotiv in strategic partnership, including investment

25-09-2014

Japan’s largest drugmaker Takeda Pharmaceutical has made a strategic investment in USA-based BioMotiv,…

BioMotivCardio-vascularFinancialImmunologicalsInflammatory diseasesJapanPharmaceuticalResearchTakeda PharmaceuticalUSA

Statins can lead to increased survival after hemorrhagic stroke, study finds

Statins can lead to increased survival after hemorrhagic stroke, study finds

24-09-2014

Patients who were treated with a statin in hospital after suffering from a hemorrhagic stroke were significantly…

Cardio-vascularHealthHemorrhagic strokePharmaceuticalResearchStatinStrokeUSA

Cardiorentis enters into financing agreement with HealthCare Royalty Partners to fund Ularitide

Cardiorentis enters into financing agreement with HealthCare Royalty Partners to fund Ularitide

17-09-2014

Privately-held Swiss pharma company Cardiorentis AG has entered into a €45 million ($58.3 million)…

Cardio-vascularCardiorentisFinancialPharmaceuticalSwitzerlandUlaritide

1 to 25 of 423 results

Back to top